Dean M. Wingerchuk

34.5k total citations · 12 hit papers
221 papers, 22.9k citations indexed

About

Dean M. Wingerchuk is a scholar working on Pathology and Forensic Medicine, Neurology and Rheumatology. According to data from OpenAlex, Dean M. Wingerchuk has authored 221 papers receiving a total of 22.9k indexed citations (citations by other indexed papers that have themselves been cited), including 138 papers in Pathology and Forensic Medicine, 134 papers in Neurology and 41 papers in Rheumatology. Recurrent topics in Dean M. Wingerchuk's work include Multiple Sclerosis Research Studies (125 papers), Peripheral Neuropathies and Disorders (93 papers) and Systemic Lupus Erythematosus Research (31 papers). Dean M. Wingerchuk is often cited by papers focused on Multiple Sclerosis Research Studies (125 papers), Peripheral Neuropathies and Disorders (93 papers) and Systemic Lupus Erythematosus Research (31 papers). Dean M. Wingerchuk collaborates with scholars based in United States, Germany and Japan. Dean M. Wingerchuk's co-authors include Brian G. Weinshenker, Claudia F. Lucchinetti, Sean J. Pittock, Vanda A. Lennon, Kazuo Fujihara, Ichiro Nakashima, Peter C. O’Brien, Michael Levy, Thomas J. Kryzer and Anu Jacob and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Brain.

In The Last Decade

Dean M. Wingerchuk

211 papers receiving 22.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

2015 3.0k citations Dean M. Wingerchuk, Brenda Banwell et al. Neurology profile →
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

2004 2.4k citations Vanda A. Lennon, Dean M. Wingerchuk et al. profile →
Revised diagnostic criteria for neuromyelitis optica

2006 2.0k citations Dean M. Wingerchuk, Vanda A. Lennon et al. Neurology profile →
The spectrum of neuromyelitis optica

2007 1.6k citations Dean M. Wingerchuk, Vanda A. Lennon et al. The Lancet Neurology profile →
The clinical course of neuromyelitis optica (Devic’s syndrome)

1999 1.4k citations Dean M. Wingerchuk, Brian G. Weinshenker et al. Neurology profile →
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis

2007 564 citations Vanda A. Lennon, S J Pittock et al. profile →
Neuromyelitis Optica Brain Lesions Localized at Sites of High Aquaporin 4 Expression

2006 552 citations Sean J. Pittock, Brian G. Weinshenker et al. profile →
Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder

2019 536 citations Sean J. Pittock, Achim Berthele et al. profile →
Brain Abnormalities in Neuromyelitis Optica

2006 523 citations Sean J. Pittock, Vanda A. Lennon et al. profile →
Neuromyelitis Optica and Non–Organ-Specific Autoimmunity

2008 448 citations Sean J. Pittock, Vanda A. Lennon et al. profile →
Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies

2014 317 citations Dean M. Wingerchuk et al. profile →
Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG–Associated Disorders

2018 256 citations A. Sebastian López‐Chiriboga, Masoud Majed et al. profile →

Peers

Countries citing papers authored by Dean M. Wingerchuk

Since Specialization

Citations

This map shows the geographic impact of Dean M. Wingerchuk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dean M. Wingerchuk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dean M. Wingerchuk more than expected).

Fields of papers citing papers by Dean M. Wingerchuk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dean M. Wingerchuk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dean M. Wingerchuk. The network helps show where Dean M. Wingerchuk may publish in the future.

Co-authorship network of co-authors of Dean M. Wingerchuk

This figure shows the co-authorship network connecting the top 25 collaborators of Dean M. Wingerchuk. A scholar is included among the top collaborators of Dean M. Wingerchuk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dean M. Wingerchuk. Dean M. Wingerchuk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cerebellar Involvement in Attacks of Aquaporin-4-IgG Positive Neuromyelitis Optica Spectrum Disorder 2024 ·Neurology Neuroimmunology & Neuroinflammation ·Alessandro Dinoto, Laura Cacciaguerra, Karl N. Krecke, John J. Chen, Dean M. Wingerchuk, Brian G. Weinshenker, Samantha A. Banks, A. Sebastian López‐Chiriboga, Cristina Valencia-Sánchez, Elia Sechi, Sean J. Pittock, Eoin P. Flanagan	0
2	Alterations in Aquaporin‐4‐IgG Serostatus in 986 Patients: A Laboratory‐Based Longitudinal Analysis 2023 ·Annals of Neurology ·Masoud Majed, Cristina Valencia-Sánchez, Jeffrey L. Bennett, James P. Fryer, (unknown), (unknown), Andrew McKeon, John R. Mills, Dean M. Wingerchuk, Vanda A. Lennon, Brian G. Weinshenker, John J. Chen, Eoin P. Flanagan, Sean J. Pittock, Amy Kunchok	15
3	Characterization of Disease Severity and Stability in NMOSD: A Global Clinical Record Review with Patient Interviews 2023 ·Neurology and Therapy ·Marco Capobianco, Marius Ringelstein, (unknown), (unknown), (unknown), Marco Aurélio Lana–Peixoto, Jiawei Wang, Ju‐Hong Min, Dean M. Wingerchuk	4
4	Understanding Treatment Decisions in Neuromyelitis Optica Spectrum Disorder: A Global Clinical Record Review with Patient Interviews 2023 ·Neurology and Therapy ·Ju‐Hong Min, Marco Capobianco, (unknown), (unknown), (unknown), Marco Aurélio Lana–Peixoto, Dean M. Wingerchuk, Jiawei Wang, Marius Ringelstein	7
5	Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders 2021 ·Multiple Sclerosis Journal - Experimental Translational and Clinical ·Vyanka Redenbaugh, Mayra Montalvo, Elia Sechi, Marina Buciuc, James P. Fryer, Andrew McKeon, Vanda A. Lennon, John R. Mills, Brian G. Weinshenker, Dean M. Wingerchuk, John J. Chen, M. Tariq Bhatti, A. Sebastian López‐Chiriboga, Sean J Pittock, Eoin P. Flanagan	31
6	CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies 2021 ·Neurology ·(unknown), (unknown), Elia Sechi, (unknown), Eelco F. M. Wijdicks, Sean J. Pittock, John J. Chen, Dean M. Wingerchuk, Brian G. Weinshenker, A. Sebastian López‐Chiriboga, Divyanshu Dubey, Jan‐Mendelt Tillema, Michel Toledano, Hemang Yadav, Eoin P. Flanagan	32
7	Does General Anesthesia Compared With Conscious Sedation Result in Better Outcomes in Acute Stroke Patients Undergoing Endovascular Therapy? 2021 ·The Neurologist ·(unknown), Bart M. Demaerschalk, Brian W. Chong, Bernard R. Bendok, (unknown), Lisa Marks, Dean M. Wingerchuk, Cumara B. O’Carroll	1
8	Long-term efficacy and safety of eculizumab monotherapy in AQP4+ neuromyelitis optica spectrum disorder (1578) 2021 ·Neurology ·Sean J. Pittock, Kazuo Fujihara, Jacqueline Palace, Achim Berthele, Ho Jin Kim, (unknown), Ichiro Nakashima, Michael Levy, Shulian Shang, Marcus Yountz, Larisa Miller, Róisín Armstrong, Dean M. Wingerchuk	1
9	Efficacy and safety of eculizumab in patients with neuromyelitis optica spectrum disorder previously treated with rituximab: findings from PREVENT 2020 ·Multiple Sclerosis Journal ·Miles Levy, Achim Berthele, (unknown), (unknown), Ichiro Nakashima, Celia Oreja‐Guevara, Jacqueline Palace, S J Pittock, (unknown), N. А. Totolyan, (unknown), (unknown), Andrea Pace, Marcus Yountz, D. Scott Lawson, (unknown), Dean M. Wingerchuk	4
10	Regional outcomes of eculizumab treatment in patients with aquaporin-4 immunoglobin G-positive neuromyelitis optica spectrum disorder: findings from the phase 3 PREVENT study 2020 ·European Journal of Neurology ·Celia Oreja‐Guevara, Jacqueline Palace, S J Pittock, Achim Berthele, (unknown), Miles Levy, Ichiro Nakashima, Andrea Pace, Larisa Miller, (unknown), Dean M. Wingerchuk	1
11	Impact of Eculizumab on Hospitalization Rates and Relapse Treatment in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: the Phase 3 PREVENT Study (1780) 2020 ·Neurology ·Ho Jin Kim, Sean J. Pittock, Achim Berthele, Kazuo Fujihara, Michael Levy, Jacqueline Palace, Ichiro Nakashima, Murat Terzi, N. А. Totolyan, Shanthi Viswanathan, Kaichen Wang, (unknown), Kenji P. Fujita, Marcus Yountz, Róisín Armstrong, Dean M. Wingerchuk	2
12	Pharmacokinetic/pharmacodynamic properties of eculizumab support established efficacy in patients with NMOSD: findings from the phase 3 PREVENT study 2020 ·European Journal of Neurology ·Achim Berthele, Celia Oreja‐Guevara, Jacqueline Palace, Dean M. Wingerchuk, S J Pittock, (unknown), Ichiro Nakashima, (unknown), (unknown), (unknown), (unknown)	3
13	Impact of eculizumab on reported quality of life in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: findings from the PREVENT study 2019 ·Multiple Sclerosis Journal ·Achim Berthele, S J Pittock, (unknown), (unknown), Miles Levy, Jacqueline Palace, Ichiro Nakashima, (unknown), N. А. Totolyan, (unknown), (unknown), Andrea Pace, K Fujita, Marcus Yountz, (unknown), Dean M. Wingerchuk, (unknown)	2
14	Impact of eculizumab on disability measures in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: phase 3 PREVENT study 2019 ·Multiple Sclerosis Journal ·Jacqueline Palace, S J Pittock, Achim Berthele, (unknown), (unknown), Miles Levy, Ichiro Nakashima, (unknown), N. А. Totolyan, (unknown), (unknown), (unknown), Marcus Yountz, (unknown), Dean M. Wingerchuk, (unknown)	1
15	Neuromyelitis Optica Spectrum Disorders 2016 ·Oxford University Press eBooks ·Dean M. Wingerchuk	8
16	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders breakdown → 2015 ·Neurology ·Dean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett, Philippe Cabre, William M. Carroll, Tanuja Chitnis, J. de Sèze, Kazuo Fujihara, Benjamin Greenberg, Anu Jacob, Sven Jarius, Marco Aurélio Lana–Peixoto, Michael Levy, Jack H. Simon, Silvia Tenembaum, Anthony Traboulsee, Patrick Waters, Kay E. Wellik, Brian G. Weinshenker	2985
17	The Clinical Utility of High Resolution Magnetic Resonance Imaging in the Diagnosis of Giant Cell Arteritis 2008 ·The Neurologist ·Julie Khoury, Joseph M. Hoxworth, Mehrdad Mazlumzadeh, Kay E. Wellik, Dean M. Wingerchuk, Bart M. Demaerschalk	6
18	The spectrum of neuromyelitis optica breakdown → 2007 ·The Lancet Neurology ·Dean M. Wingerchuk, Vanda A. Lennon, Claudia F. Lucchinetti, Sean J. Pittock, Brian G. Weinshenker	1643
19	Multiple Sclerosis: Current Pathophysiological Concepts 2001 ·Laboratory Investigation ·Dean M. Wingerchuk, Claudia F. Lucchinetti, John H. Noseworthy	166
20	MULTIPLE SCLEROSIS: EPIDEMIOLOGY, GENETICS, CLASSIFICATION, NATURAL HISTORY, AND CLINICAL OUTCOME MEASURES 2000 ·Neuroimaging Clinics of North America ·Dean M. Wingerchuk, (unknown)	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact